Missed opportunities: Despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains

Sumeet Subherwal, Manesh R. Patel, Lars Kober, Eric D. Peterson, William S. Jones, Gunnar H. Gislason, Jeffrey Berger, Christian Torp-Pedersen, Emil L. Fosbol

Research output: Contribution to journalArticlepeer-review

Abstract

Background-Patients with peripheral artery disease (PAD) are at high risk of cardiovascular events and benefit from aggressive secondary prevention; however, changes in the use of cardioprotective medications after incident diagnosis of PAD have not been well described. Methods and Results-We used Danish nationwide administrative registries (2000-2007) to identify 2 groups with incident PAD: PAD alone (n=34 160) and PAD with history of coronary artery disease (CAD) (n=9570). With the use of a comparator with incident CAD alone (n=154 183), we assessed temporal trends and comparative use of cardioprotective medications. Relative differences in medication use were examined by using multivariable logistic regression. Use of medications improved temporally among both groups: for PAD alone, any antiplatelet use increased from 29% to 59% from 2000 to 2007 (P<0.0001), whereas statin use increased 6-fold (9%-56%; P<0.0001). However, use of these therapies by 18 months after incident diagnosis for both PAD groups remained modest and lower in comparison with CAD alone (any antiplatelet, 53% versus 66%; statins, 40% versus 52%; angiotensin-converting enzyme inhibitors, 20% versus 29%). Relative to CAD alone, patients with PAD alone were less likely to use any antiplatelet (adjusted odds ratio, 0.50; 95% confidence interval, 0.49-0.52), statins (adjusted odds ratio, 0.50; 95% confidence interval, 0.48-0.52), or angiotensin-converting enzyme inhibitors (adjusted odds ratio, 0.51; 95% confidence interval, 0.49-0.53) by 18 months. Conclusions-Despite improvement in the use of cardioprotective medications over time, patients with PAD alone remain less likely than those with CAD alone to use these agents.

Original languageEnglish (US)
Pages (from-to)1345-1354
Number of pages10
JournalCirculation
Volume126
Issue number11
DOIs
StatePublished - Sep 11 2012
Externally publishedYes

Keywords

  • coronary disease
  • drugs
  • peripheral vascular disease
  • prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Missed opportunities: Despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains'. Together they form a unique fingerprint.

Cite this